[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-heart-failure":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,42,66,89,118,146,177,206,241,263,286,306,327,353,378,407,436,455,475,501,522,545,566,585,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100626348","ketone-ester-for-treatment-of-acute-heart-failure-100626348",false,"NCT07434466","Ketone Ester for Treatment Of Acute Heart Failure","KETO-AHF: Ketone Ester for Treatment Of Acute Heart Failure: A Vanguard Randomized Controlled Trial","KETO-AHF","Domain-Specific Inclusion Criteria:\n\n1. Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure \\[21\\]\n2. Admitted to the hospital for less than 48 hours\n3. Estimated glomerular filtration rate above 15 mL\u002Fmin\u002F1.73m²\n4. NT-proBNP ≥ 1000 pg\u002Fml\n\nDomain-Specific Exclusion Criteria:\n\n1. Type 1 diabetes mellitus\n2. Patients on mechanical circulatory support\n3. Patients on more than one inotrope or on inopressors\n4. Patients on dialysis\n5. Patients with non-functioning enteral tracks","ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.",[28],"Acute Heart Failure","NOT_YET_RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-04","ACTUAL",{"date":35,"type":22},"2026-07",{"date":37,"type":22},"2028-03",{"name":39,"class":40},"University of Alberta","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100640947","phase-4-infusion-of-furosemide-to-improve-diuretic-efficiency-in-acute-heart-failure-100640947","NCT07577596","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)","INFUSE-AHF","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure with volume overload\n* At least 1 sign of volume overload\n* Anticipated intravenous furosemide treatment for at least 3 days\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Shock\n* Patient requiring treatment with inotropes or vasopressors\n* Current or planned use of renal replacement therapy or ultrafiltration\n* Patient with a renal transplant\n* Patients who are pregnant or breastfeeding\n* Severe hypokalaemia, defined as potassium less than 2.5 mmol\u002FL, or severe hyponatremia, defined as sodium less than 125 mmol\u002FL\n* Allergy to furosemide and its components",{"count":51,"type":22},436,[53],"PHASE4","Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine.\n\nFurosemide is a commonly used water-removing medicine that is given into a vein to treat fluid overload. It can be given in different ways. One way is as a continuous infusion, where the medicine is given slowly over time through a pump. Another way is as repeated injections given several times a day. It is not known whether one of these ways is better than the other for removing excess fluid in people with acute heart failure.\n\nThe purpose of this study is to compare two ways of giving furosemide into a vein: Continuous infusion started with an initial extra dose, and bolus injections given three times a day. About 436 adults admitted to hospitals in Denmark with acute heart failure and fluid overload will take part. Participants will be randomly assigned to one of the two treatment groups. This means that chance will decide which treatment method each participant receives.\n\nThe main thing the researchers will measure is how much body weight participants lose about 3 days after randomization. Weight loss is used as a measure of how much excess fluid has been removed.",[28,56],"Volume Overload","2026-05-05",{"date":59,"type":33},"2026-05-11",{"date":61,"type":22},"2026-05-01",{"date":63,"type":22},"2027-10-01",{"name":65,"class":40},"University of Aarhus",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100362434","mri-assessment-of-pulmonary-edema-in-acute-heart-failure-100362434","NCT03999138","MRI Assessment of Pulmonary Edema in Acute Heart Failure","MAP-AHF","Inclusion Criteria:\n\n* 18 years of age or older and willing\u002Fable to provide informed consent\n* patients being treated for acute heart failure (including those patients with both reduced and preserved ejection fraction)\n* patients receiving medical therapy for pulmonary edema by current standard of care (including oral or IV diuretics)\n* patients identified within 48 hours of initiation of medical therapy for pulmonary edema, defined as the time of first diuretic (IV or PO) or escalation of existing diuretic therapy administered within the ED or hospital\n\nExclusion Criteria:\n\n* contraindication to MRI\n* patient too critically ill\u002Funstable as per the clinical care team for transport to MRI scanner within the required scanning window\n* moderate to severe dementia",{"count":74,"type":22},300,"OBSERVATIONAL","Researchers are testing a more accurate way to measure how much fluid is in the lungs (also called pulmonary edema, or \"increased lung water\") in people with Heart Failure (HF) using MRI (Magnetic Resonance Imaging). There is little known about the exact level of lung water in patients with AHF or how these levels change from the time of hospital admission to discharge. The purpose of this research study is to measure the lung water in patients hospitalized for HF, to determine the change in lung water over the course of hospitalization and treatment, and to find out if lung water levels can predict if patients are higher or lower risk for returning to the hospital or dying from heart failure.",[28,78],"Pulmonary Edema With Heart Failure","RECRUITING","2026-05-04",{"date":82,"type":33},"2026-05-08",{"date":84,"type":33},"2019-01-02",{"date":86,"type":22},"2027-12-31",{"name":39,"class":40},2,{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100516720","phase-3-a-study-to-determine-the-efficacy-and-safety-of-finerenone-on-morbidity-and-mortality-among-hospitalized-heart-failure-patients-100516720","NCT06008197","A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients","Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)","REDEFINE-HF","Inclusion Criteria:\n\n* Provide written informed consent\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Current hospitalization or recently discharged (during or within 30 days of discharge) with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher)\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg\u002FmL or B-type natriuretic peptide (BNP) ≥125 pg\u002FmL for patients without atrial fibrillation (AF); or elevated NTproBNP ≥1500 pg\u002FmL or BNP ≥375 pg\u002FmL for patients with AF\n\nExclusion Criteria:\n\n* Current or planned long-term treatment with a mineralocorticoid receptor antagonist (MRA)\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Estimated glomerular filtration rate (eGFR) \\\u003C25 mL\u002Fmin\u002F1.73m² or potassium \\>5.0 mmol\u002FL at screening\n* Acute myocardial infarction due to plaque rupture, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Hemodynamically significant (severe) uncorrected primary cardiac valvular disease\n* Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or known pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)",{"count":98,"type":22},5200,[100],"PHASE3","Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.",[103,28],"Heart Failure",[105,106,107,108],"Heart failure","Preserved ejection fraction","Mildly reduced ejection fraction","Hospitalized",{"date":110,"type":33},"2026-05-06",{"date":112,"type":33},"2024-01-17",{"date":114,"type":22},"2027-12",{"name":116,"class":40},"Colorado Prevention Center",299,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100460483","phase-4-optimized-treatment-of-pulmonary-edema-or-congestion-100460483","NCT05276219","Optimized Treatment of Pulmonary Edema or Congestion","Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial","Decongest","Inclusion criteria\n\n1. Age ≥ 18 years\n2. Acute (within minutes to days) onset or worsening of subjective dyspnea\\*\n3. Systolic blood pressure ≥100 mmHg\n4. Oxygen saturation \\\u003C94% or need of oxygen\n5. Signs or suspicion of congestion (peripheral edema, rales, and\u002For clinical suspicion of congestion) \\*\n\n   * by the best assessment from a medical doctor. Inclusion must not wait on x-ray or other measures: patients suspected of pulmonary congestion should be included immediately.\n\nExclusion criteria\n\n1. More than 40 mg IV furosemide within the last three hours before randomization including prehospital treatment.\n2. More than 3 hours from hospital-admission to randomization\n3. Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias with HR \\> 180 or \\\u003C 40 bpm.\n4. Suspected severe infection or sepsis.\n\nExclusion criteria are purposely liberal, so patients can be included in accordance with everyday clinical practice. However, a safety criterion will be implemented:\n\nIf blood pressure drops below 90 mmHg in 2 measurements with 5 minutes apart and\u002For if urine production is below 50 ml after 1 hour, the intervention will be stopped, and patients can receive furosemide and nitrates freely.\n\nWe purposely chose not to exclude patients with aortic stenosis, since observational studies did not find excess risk of given nitrates to patients with pulmonary edema and aortic stenosis",{"count":127,"type":22},1104,[53],"Background:\n\nIntravenous (IV) loop-diuretics have been a key component in treating pulmonary edema since the nineteen sixties and has a Class 1 recommendation in the 2021 European Society of Cardiology guidelines for heart failure. Conversely, vasodilation was downgraded in the treatment of acute heart failure due to a lack of trials that compare vasodilation with loop-diuretics in a hyperacute clinical setting. This clinical equipoise will be tested in a trial including patients with pulmonary congestion immediately at hospital admission.\n\nPrimary objective:\n\nTo determine the superior strategy of loop-diuretics (furosemide), vasodilation (nitrates) or the combination during emergency treatment.\n\nDesign: Investigator-initiated, randomized, double-blinded, placebo-controlled trial with 1:1:1 allocation.\n\nIntervention:\n\nIntervention-phase will last 6 hours from study-inclusion, and patients will be allocated to one of three groups:\n\n* Boluses of 40 mg IV furosemide + nitrate-placebo as soon as possible and repeated up to 10 times.\n* Boluses of 3 mg IV isosorbide dinitrate + furosemide-placebo as soon as possible.\n* Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg as soon as possible.",[131,132,28],"Pulmonary Edema","Congestive Heart Failure",[134,135],"acute heart failure","Pulmonary edema","2026-04-17",{"date":138,"type":33},"2026-04-22",{"date":140,"type":33},"2023-09-14",{"date":142,"type":22},"2027-05-31",{"name":144,"class":40},"Rigshospitalet, Denmark",4,{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":75,"phases":4,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":41},"100632069","characterisation-of-phenotypes-in-acute-heart-failure-patients-100632069","NCT07508891","Characterisation of phenotYpes in aCute Heart faiLure patiEnts","CYCLE","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure.\n* Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation de to a different cause. Out-patients with acute heart failure are not included.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* No written informed consent.",{"count":154,"type":22},1000,"10 Years","An observational cohort study to evaluate the benefit of functional parameters, radiomics and blood biomarkers to predict the outcome of patients with acute heart failure.",[28,158,159],"Decompensated Heart Failure","Cardiogenic Shock",[161,134,162,163,164,165,166,167],"cardiogenic shock","heart failure","biomarker","biobank","cohort study","phenotyping","risk prediction","2026-03-30",{"date":170,"type":33},"2026-04-02",{"date":172,"type":33},"2019-03-01",{"date":174,"type":22},"2030-12-31",{"name":176,"class":40},"Universitätsklinikum Hamburg-Eppendorf",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100551854","investigating-acute-heart-failure-decongestion-guided-by-lung-ultrasonography-100551854","NCT06465498","Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography","Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography (IcarUS) : a Randomized Controlled Trial","IcarUS","Inclusion Criteria:\n\n* ≥ 18 years old\n* Planned or actual admission to intermediate care units, general internal medical or cardiology wards\n* Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis)\n* Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng\u002Fl).\n\nKey Exclusion Criteria:\n\n* Known isolated right heart failure\n* Systolic blood pressure \\\u003C90 mmHg, mean arterial pressure \\\u003C65 mmHg at the moment of inclusion\n* The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or metastasis, acute respiratory distress syndrome, pulmonary contusion\n* Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months\n* Unwillingness to give consent\n* Subjects who are pregnant or breastfeeding\n* Hospitalisation for palliative care and probable end-life within 30 days",{"count":186,"type":22},222,[25],"The goal of this clinical trial is to investigate whether a lung ultrasonography (LUS)-guided decongestion strategy in adults hospitalized for acute heart failure (AHF) can improve patient-centered outcomes.\n\nThe main questions it aims to answer are:\n\n* Does this strategy shorten the length of stay and reduce early hospital readmissions?\n* Does this strategy improve patients' symptoms and quality of life ?\n\nResearchers will compare LUS to physical examination (PE).",[28],[191,192,193,194,195],"Lung ultrasonography","Ultrasound","Point-of-care ultrasonography","Decongestion","Diuretic","2026-03-26",{"date":198,"type":33},"2026-04-01",{"date":200,"type":33},"2024-10-22",{"date":202,"type":22},"2027-04-30",{"name":204,"class":40},"Antonio Leidi",5,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":213,"minAge":19,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100615662","phase-4-pharmacological-optimization-in-prevention-in-heart-failure-a-sex-gap-100615662","NCT07295522","Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","PopS-HF","Inclusion Criteria:\n\n1. Female patients \\>18 \\\u003C85 years.\n2. Hospital admission within the 72 hours prior to Screening for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and\u002For symptoms of heart failure such as edema and\u002For positive rales on auscultation.\n3. All measures within 24 hours prior to Randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm.\n4. All measures within 24 hours prior to Randomization of serum potassium ≤ 5.0 mEq\u002FL (mmol\u002FL).\n5. Biomarker criteria for persistent congestion:\n\n   5.1. At Screening, NT-proBNP \\>1,800 pg\u002FmL (2,350 pg\u002FmL in case of atrial fibrillation) 5.2. At the time of Randomization (1-2 days prior to discharge), NT-proBNP \\>1,000 pg\u002FmL (1,300 pg\u002FmL in case of Atrial Fibrillation) to ensure the persistence of congestion and the acuity of the index episode).\n6. At 1 week prior to admission, at Screening, and at Visit 2 6.1. If EF\\\u003C50% (ie HFrEF or HFmrEF) either \\\u003C½ the optimal dose of ACEi\u002FARB\u002FARNi and MRA and BB or no SGLT2i (see Table) must have been prescribed 6.2. If EF\\>50% (ie HFpEF): \\\u003C½ the optimal dose of MRA (see Table) or no SGLT2i.\n7. Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Male patients\n2. Age \\\u003C 18 or \\> 85 years.\n3. Mechanical ventilation (not including CPAP\u002FBIPAP) in the 24 hours prior to Screening.\n4. Significant pulmonary disease contributing substantially to the patients' dyspnoea such as FEV1 \\\u003C1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as primary pulmonary hypertension or recurrent pulmonary embolism.\n5. Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac resynchronization therapy (CRT) device implantation within 3 months, or percutaneous transluminal coronary intervention (PTCI), within 1 month prior to Screening or during the index event.\n6. Index Event (admission for Acute Heart Failure) triggered primarily by a correctable aetiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation\u002Fflutter with sustained ventricular response \\>130 beats per minute, or bradycardia with sustained ventricular arrhythmia \\\u003C45 beats per minute), infection, severe anaemia, acute coronary syndrome, pulmonary embolism, exacerbation of Chronic Obstructive Pulmonary Disease (COPD), planned admission for device implantation or severe non-adherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not an exclusion.\n7. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy.\n8. History of heart transplant or on a transplant list or using or planned to be implanted with a ventricular assist device.\n9. Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to screening that is untreated.\n10. Presence at Screening of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation, or the presence of any hemodynamically significant obstructive lesion\n11. Active infection at any time during the AHF hospitalization prior to Randomization based on abnormal temperature and elevated WBC or need for intravenous antibiotics.\n12. Stroke or Transient Ischemic Attack (TIA) within the 3 months prior to Screening.\n13. Primary liver disease considered to be life threatening.\n14. Renal disease or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2 (as estimated by the simplified MDRD formula) at Screening or history of dialysis.\n15. Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \\\u003C 6 months.\n16. Prior (defined as less than 30 days from screening) or current enrollment in a CHF trial or participation in an investigational drug or device study within the 30 days prior to screening or 5 half-lives of the study drug, whichever is longer.\n17. Discharge for the AHF hospitalization anticipated to be \\>14 days from admission, or to a long-term care facility. Randomization must occur within 12 days following admission and at 1-2 days prior to anticipated discharge.\n18. Inability to comply with all study requirements, due to major co-morbidities, social or financial issues or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and\u002For comply with the protocol instructions or follow-up procedures.\n19. Pregnant or nursing (lactating) women.\n20. Hypersensitivity to the active substance or to any of the excipients as indicated in Summary of Product Characteristics of Investigational Medicinal Product (IMPs).\n21. Angioedema.\n22. Severe heart failure (NYHA class IV).","FEMALE","85 Years",{"count":216,"type":22},368,[53],"The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure. It will also investigate the safety and the tolerance of these treatments when given at full guideline-recommended doses.\n\nThe main questions it aims to answer are:\n\n1. Does intensive medication optimization reduce death or hospital readmissions for heart failure within one year?\n2. Do women benefit as much as men from intensive and full-dose heart failure therapy?\n3. Is this treatment protocol safe and feasible also in women?\n\nResearchers will compare two groups of women hospitalized for heart failure:\n\n* High-intensity care: starting and increasing all recommended heart-failure medications as quickly as possible and monitoring patients closely during the first weeks after discharge.\n* Usual care: medications are started and adjusted gradually, according to the judgment of the treating cardiologist and the patient's usual care team.\n\nThe study will follow participants for 12 months to see whether the high-intensity strategy reduces death, hospital readmission for heart failure, or worsening symptoms. It will also evaluate side effects, medication tolerance, and quality of life.\n\nParticipants will be randomly assigned to one of the two groups, attend regular follow-up visits for one year, complete a short quality-of-life questionnaire (EQ-5D).\n\nThis study will include about 360 women from 13 hospitals in Italy. It is sponsored by IRCCS Policlinico San Donato and funded by the Italian Medicines Agency (AIFA).",[103,28,220,221,222],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)","Heart Failure With Mildly Reduced Ejection Fraction",[162,224,225,226,227,228,229,230,231],"women","GDMT","Pharmacological Optimization","phase IV","High intensity up-titration","Secondary prevention","Sex differences","Real world data","2026-03-25",{"date":168,"type":33},{"date":235,"type":22},"2026-04-08",{"date":237,"type":22},"2028-06-08",{"name":239,"class":40},"IRCCS Policlinico S. Donato",13,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":213,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":41},"100627315","integrating-aerobic-respiratory-and-cognitive-training-in-acute-heart-failure-100627315","NCT07447037","Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure","Inclusion Criteria:\n\n* Age between 50-65 years.\n* All patients are male.\n* Diagnosed with acute heart failure according to ESC guidelines.\n* Hemodynamically stable for at least 24 hours.\n* Able to follow simple verbal commands and participate in training.\n\nExclusion Criteria:\n\n* Unstable angina or recent myocardial infarction (\\\u003C 4 weeks).\n* Severe uncontrolled arrhythmias or advanced atrioventricular block.\n* Severe pulmonary disease (e.g., advanced COPD, restrictive lung disease).\n* Neurological disorders causing cognitive or motor disability.\n* Orthopedic or musculoskeletal conditions preventing upper-limb activity.\n* Severe visual or auditory impairment limiting participation in cognitive training.","50 Years","65 Years",{"count":250,"type":22},40,[25],"The purpose of this study is to investigate the impact of integrating aerobic, respiratory and cognitive training in acute heart failure.",[28],"2026-02-26",{"date":256,"type":33},"2026-03-03",{"date":258,"type":22},"2026-03-07",{"date":260,"type":22},"2026-04-30",{"name":262,"class":40},"Cairo University",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":285},"100469434","phase-3-early-treatment-with-a-sodium-glucose-co-transporter-2-inhibitor-in-high-risk-patients-with-acute-heart-failure-100469434","NCT05392764","Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Empagliflozin in Patients With Acute Heart Failure","EMPA-AHF","Inclusion Criteria:\n\nPatients who meet the below inclusion criteria will be randomized within 12 h after presentation to the hospital\n\n1. Age of ≥20\\*\n2. Hospitalized with a diagnosis of acute heart failure, requiring intravenous loop diuretic therapy, and with all of the following characteristics:\n\n   i. Dyspnoea at rest or induced by slight exertion ii. At least two of the following findings: jugular venous distention, pulmonary rales, lower leg edema, and pulmonary congestion on chest X-ray iii. If the patient has a sinus rhythm at the time of admission, BNP ≥350 pg\u002FmL or NT-proBNP ≥1400 pg\u002FmL; if the patient has atrial fibrillation at the time of admission, BNP ≥500 pg\u002FmL or NT-proBNP ≥2000 pg\u002FmL. For patients taking an angiotensin receptor neprilysin inhibitor, only the reference value for NT-proBNP will be applicable.\n3. At least one of the following characteristics:\n\n   i. eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2, as calculated using the CKD Epidemiology Collaboration for JapaneseModification of Diet in Renal Disease formula ii. Already taking ≥40 mg of oral furosemide during the period before hospitalization. For patients on loop diuretics other than furosemide, the following conversion should be used: oral furosemide 20 mg = oral azosemide 30 mg = oral torasemide 5 mg.\n\n   iii. Urine output of \\\u003C300 mL during the 2 h following an appropriate dose of intravenous furosemide administered after hospitalization. An appropriate dose of intravenous furosemide is 20 mg for patients who have not been taking furosemide regularly before hospitalization and is the same as, or greater than, the daily oral dose for patients who have been taking furosemide regularly before hospitalization.\n4. Provided written consent to participate in the study \\*If the patient is 90 years of age or older and cognitive decline is considered necessary, Mini-Cog should be used to confirm that its score is not less than 3.\n\nExclusion Criteria:\n\n1. eGFR \\\u003C20 mL\u002Fmin\u002F1.73m2 at the time of admission\n2. Already taking an SGLT2i within 3 months prior to hospitalization\n3. Type 1 diabetes mellitus\n4. Systolic blood pressure \\\u003C90 mmHg\n5. Expected to newly require treatment with thiazide, tolvaptan, or carperitide within 48 hours of study drug administration\n6. Main cause of acute heart failure hospitalization is not fluid retention (e.g., persistent ventricular tachycardia, persistent atrial fibrillation\u002Fatrial flutter with a ventricular response rate of ≥130 bpm, persistent bradycardia with a ventricular response rate of \\\u003C45 bpm, an infection, severe anemia, and an acute exacerbation of COPD)\n7. Acute coronary syndrome, pulmonary thromboembolism, or a cerebrovascular accident is the main cause of the present hospitalization.\n8. At risk of ketoacidosis or hyperosmolar hyperglycaemia\n9. On dialysis, including peritoneal dialysis, or the initiation of dialysis during hospitalization is planned\n10. Pregnant or lactating women\n11. Underwent the following therapeutic interventions within 30 days: cardiovascular surgery (e.g., coronary artery bypass grafting, surgery for valvular heart disease, transcatheter aortic valve implantation, percutaneous coronary intervention, percutaneous edge-to-edge mitral valve repair, and other types of surgery at the investigator's discretion) and implantation of an implantable defibrillator, cardiac resynchronization therapy defibrillator, or implantable ventricular-assist device\n12. A diagnosis of acute coronary syndrome, cerebral infarction, or transient ischemic attack made within 90 days\n13. Ventricular tachycardia with syncope within 90 days\n14. Heart transplant recipient or listed for heart transplantation and expected to undergo transplantation during the present treatment; implanted with an implantable ventricular-assist device or expected to require an implantable ventricular-assist device during the present treatment; or expected to switch to palliative care\n15. Intubated at the time of screening or expected to require intubation within within 48 hours of study drug administration\n16. Severe valvular heart disease expected to be treated with thoracostomy or catheterization (a reason to exclude secondary mitral or tricuspid regurgitation due to reduced cardiac function does not exist, except for the absence of a plan to perform cardiac surgery or therapeutic catheterization)\n17. A diagnosis of secondary cardiomyopathy such as amyloidosis, cardiac sarcoidosis, hemochromatosis, Fabry disease, and muscular dystrophy. Heart failure due to takotsubo cardiomyopathy, obstructive hypertrophic cardiomyopathy, complex congenital heart disease (as determined by the investigator), or pericardial constriction.\n18. A diagnosis of peripartum cardiomyopathy made within 6 months\n19. Active myocarditis\n20. Presence of uncontrolled thyroid disease\n21. Acute cardiac structural abnormalities (e.g., acute mitral regurgitation due to ruptured chordae tendineae)\n22. Symptomatic bradycardia or complete atrioventricular block, being treated with a temporary pacemaker implantation at the time of admission, or expected to require a temporary pacemaker implantation in the future. Patients who have already been treated with a permanent pacemaker implantation do not meet the exclusion criteria.\n23. Serious liver disorder (an increase in AST, ALT, or ALP level ≥3 times the upper limit of normal) or cirrhosis with varices or other findings suggestive of portal hypertension\n24. Alcohol use disorder of at least mild severity according to the DSM-V\n25. A diagnosis of active malignancy or suspected active malignancy made within 2 years\n26. Coexisting diseases other than heart failure with an expected survival prognosis of ≤1 year\n27. Participation in a clinical study of another drug 30 days before hospitalization\n28. Patients considered to require fasting at screening.\n29. Other conditions likely to interfere with the patient's safety or compliance with the protocol\n30. Other patients who are considered unsuitable by the principal investigator or other investigators","20 Years",{"count":273,"type":22},444,[100],"The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.",[28],"2026-02-11",{"date":279,"type":33},"2026-02-13",{"date":281,"type":33},"2022-09-10",{"date":86,"type":22},{"name":284,"class":40},"Juntendo University",69,{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":305},"100623516","phase-4-efficacy-and-safety-with-early-treatment-of-finerenone-in-hospitalized-patients-with-heart-failure-100623516","NCT07397650","Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure","FACILITATE-HF","Patients eligible for inclusion in this study meet all of the following criteria: \\\u003Cbr\\>Inclusion Criteria:\n\n1. Patients ≥18 years of age, male or female\\\u003Cbr\\>\n2. Current hospitalization with AHF requiring intravenous loop diuretics or vasodilators during the index admission\\\u003Cbr\\>\n3. Patients have to have at least one of new or worsening symptoms due to HF and one of new or worsening physical examination findings due to HF \\\u003Cbr\\> (i) symptom\\\u003Cbr\\> dyspnoea, decreased exercise tolerance, or fatigue\\\u003Cbr\\> (ii) physical examination\\\u003Cbr\\> peripheral edema, increasing abdominal distention or ascites, pulmonary rales\u002Fcrackles\u002Fcrepitations, increased jugular venous pressure and\u002For hepatojugular reflux, S3 gallop, clinically significant or rapid weight gain\\\u003Cbr\\>\n4. Patients who are not hemodynamically unstable as defined by meeting the following criteria\\\u003Cbr\\>\n\n   1. Systolic blood pressure ≥100 mmHg and no symptoms of hypotension within 6 hours prior to randomization\\\u003Cbr\\>\n   2. No increase in intravenous diuretic dose or intravenous vasodilators within 6 hours prior to randomization with worsening HF symptom\\\u003Cbr\\>\n   3. Without cardiogenic shock, no use of inotropes or vasopressors, no use of mechanical circulatory support, not requiring intubation after admission, and not expected to require inotropes, vasopressors, mechanical circulatory support or intubation during the index hospitalization\\\u003Cbr\\>\n5. NTproBNP ≥1500 pg\u002FmL or BNP ≥375 pg\u002FmL (For patients treated with ARNI in the previous 4 weeks prior to randomization, only NT-proBNP values should be used)\\\u003Cbr\\>\n6. Most recent LVEF ≥40% within the past 1 year \\\u003Cbr\\>\n7. Randomization within 24 hours after admission, and drug administration within 36 hours after admission \\\u003Cbr\\>\n8. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\\\u003Cbr\\>\n9. Signed informed consent must be obtained prior to participation in the study\\\u003Cbr\\>\n\nExclusion Criteria:\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C25 mL\u002Fmin\u002F1.73m2 by CKD-EPI Creatinine Equation (2021) at screening\\\u003Cbr\\>\n2. Serum\u002Fplasma potassium \\>5.0 mmol\u002FL at screening\\\u003Cbr\\>\n3. Patients who cannot receive oral treatment\\\u003Cbr\\>\n4. Use of eplerenone, spironolactone, esaxerenone or potassium-sparing diuretic within 30 days before randomization \\\u003Cbr\\>\n5. Known hypersensitivity to the study intervention (active substance or excipients)\\\u003Cbr\\>\n6. Systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or inducers within 7 days before randomization or is expected to be used during the study period (e.g. itraconazole, ritonavir, indinavir, cobicistat, clarithromycin).\\\u003Cbr\\>\n7. Participants who require treatment with more than one ACEI, ARB or angiotensin-receptor neprilysin inhibitor (ARNI) simultaneously\\\u003Cbr\\>\n8. Acute heart failure in which other diseases are the main cause of symptoms and signs (chronic obstructive pulmonary disease, anemia, etc.)\\\u003Cbr\\>\n9. Patients who are on dialysis including peritoneal dialysis or in whom the initiation of dialysis during the study period\\\u003Cbr\\>\n10. Pregnant or lactating female\\\u003Cbr\\>\n11. Acute coronary syndrome, pulmonary thromboembolism, stroke, or transient ischemic attack within 90 days before randomization.\\\u003Cbr\\>\n12. Have undergone the following therapeutic intervention within 30 days before randomization: cardiovascular surgery (e.g., coronary artery bypass grafting, surgery for valvular heart disease, transcatheter aortic valve implantation, percutaneous coronary intervention, percutaneous edge-to-edge mitral valve repair, and other types of surgery at the investigator's discretion) and implantation of an implantable defibrillator, or a cardiac resynchronization therapy defibrillator.\\\u003Cbr\\>\n13. Heart transplant recipients or patients listed for heart transplantation who are expected to undergo transplantation during the study, patients implanted with an implantable ventricular-assist device, patients expected to require an implantable ventricular-assist device during the study, and patients expected to switch to palliative care during the study.\\\u003Cbr\\>\n14. Coronary or valvular heart disease likely to require surgical or percutaneous intervention within the study period (there is no reason to exclude secondary mitral or tricuspid regurgitation due to reduced cardiac function, except for the absence of a plan to perform cardiac surgery or therapeutic catheterization)\\\u003Cbr\\>\n15. Secondary cardiomyopathy such as amyloidosis, cardiac sarcoidosis, hemochromatosis, Fabry's disease, chemotherapy induced cardiomyopathy, and muscular dystrophy. Heart failure due to takotsubo cardiomyopathy, obstructive hypertrophic cardiomyopathy, complex congenital heart disease (as determined by the investigator), pericardial constriction, right heart failure in absence of left-sided structural disease\\\u003Cbr\\>\n16. Acute cardiac structural abnormalities (e.g., acute mitral regurgitation due to ruptured chordae tendineae and infective endocarditis)\\\u003Cbr\\>\n17. Peripartum cardiomyopathy diagnosed within 6 months before randomization.\\\u003Cbr\\>\n18. Active myocarditis at randomization.\\\u003Cbr\\>\n19. Patients with symptomatic bradycardia or complete atrioventricular block who are being treated with temporary pacemaker implantation at the time of admission, or who are expected to require temporary or permanent pacemaker implantation in the future. Patients who have already been treated with permanent pacemaker implantation do not meet the exclusion criteria\\\u003Cbr\\>\n20. Presence of uncontrolled thyroid disease\\\u003Cbr\\>\n21. Addison's disease\\\u003Cbr\\>\n22. Hepatic insufficiency classified as Child-Pugh C \\\u003Cbr\\>\n23. Patients with excessive alcohol intake (15+ drinks\u002Fweek for men, 8+ drinks\u002Fweek for women)\\\u003Cbr\\>\n24. Any other condition or therapy, which would make the participant unsuitable for this study and will not allow participation for the full planned study period (e.g. active malignancy or other condition limiting life expectancy to less than 12 months)\\\u003Cbr\\>\n25. Patients with dementia. If a sub-investigator determines that confirmation of cognitive impairment is necessary, it must be verified that the Mini-Cog score is not less than 4.\\\u003Cbr\\>\n26. Participation in another interventional clinical study (e.g. phase 1 to 3 clinical studies) or treatment with another investigational medicinal product within 30 days prior to randomization.Other conditions likely to interfere with the patient's safety or compliance with the protocol\\\u003Cbr\\>\n27. Patients deemed unsuitable by the principal investigator or sub investigator",{"count":294,"type":22},550,[53],"FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.",[28],"2026-02-08",{"date":277,"type":33},{"date":301,"type":22},"2026-02",{"date":303,"type":22},"2028-09-30",{"name":284,"class":40},21,{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":41},"100561260","a-pragmatic-observational-study-of-congestion-profiles-in-patients-with-acute-heart-failure-100561260","NCT06587854","a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure","a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart","PROFILE-AHF","Inclusion Criteria:\n\n* Able and willing to give written informed consent\n* Age ≥ 18 years\n* Male or female\n* Primary diagnosis of acute heart failure at presentation, with signs and symptoms of tissue decongestion. Diagnosis is based on the criteria in the ESC HF guidelines (1)\n* Requirement of intravenous loop diuretics\n\nExclusion Criteria:\n\n* Patients with severe kidney dysfunction (in need for ultrafiltration or dialysis)\n* Previous participation in this study\n* Inability to follow instructions\n* Dyspnoea or oedema primarily due to non-cardiac causes",{"count":315,"type":22},270,"The goal of this observational is to study the prevalence of distinct congestion phenotypes and study their association with response to therapy and outcomes in acute heart failure patients. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\n* Primary objective: to study the prevalence of distinct congestion phenotypes\n* Other objectives (including):\n\n  * Response to therapy as assessed by\n\n    * Natriuresis after 24 hours\n    * Rehospitalization and\u002For deats after 6 months\n  * Length of hospital stay\n  * Congestion at discharge\n  * Changes in filling pressures over time\n  * Relationship between liver stiffness, as assessed with Fibroscan and congestion\n  * Substudy: glycosaminoglycan netword and endothial glycocalyx\n\nParticipants will undergo several extra study related measurements:\n\n* Assessment of filling pressures with ultrasound\n* Ultrasound investigation of the lungs and kidneys\n* Fibroscan of the liver\n* Sidestream darkfield imaging sublingual\n* As part of substudy GLYCO-AHF: skin biopsy to determine glycocalyx, as well as salt and water content.\n* As part of substudy PREACH-AHF: the effects of peripheral venous congestion and endothelial dysfunction on a large screen of plasma proteins",[28],"2025-09-02",{"date":320,"type":33},"2025-09-10",{"date":322,"type":33},"2025-05-01",{"date":324,"type":22},"2029-12-31",{"name":326,"class":40},"University Medical Center Groningen",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":145},"100258043","loop-diuretic-therapy-in-acutely-decompensated-heart-failure-100258043","NCT02638142","Loop Diuretic Therapy in Acutely Decompensated Heart Failure","Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome","DIUR-AHF","Inclusion Criteria:\n\n* Patients over 18 years;\n* Patients with diagnosis of ADHF(dyspnea, orthopnea, peripheral edema or major fatigue and at least two clinical signs including rales, hepatomegaly, pulmonary congestion on chest radiography, jugular vein dilatation, or a third heart sound);\n* Blood BNP \\> 100 pg\u002FmL;\n\nADHF: Acute Decompensated Heart Failure; BNP: B-type Natriuretic Peptide; IV: IntraVenous; LVEF: Left Ventricular Ejection Fraction.\n\nExclusion Criteria:\n\n* Patients who receive more than 40 mg of IV furosemide;\n* End-Stage renal disease or renal replacement therapy;\n* Recent myocardial infarction (within thirty days of screening);\n* Systolic blood pressure \\\u003C 80 mmHg;\n* Creatinine levels \\> 4 mg\u002FdL;\n* Patients affected by sepsis, liver diseases, inflammatory diseases or neoplastic diseases.",{"count":336,"type":22},370,"DiurHF is a prospective, multicenter, observational, study that compares continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF. Previous pilot study design was planned to anticipate a larger multicenter trial able to definitively evaluate the optimal loop diuretic use strategy in patients with ADHF.",[28],[340,162,341,342,343],"loop diuretic","renal dysfunction","congestion signs","BNP","2025-08-04",{"date":346,"type":33},"2025-08-08",{"date":348,"type":33},"2015-12",{"date":350,"type":22},"2028-01",{"name":352,"class":40},"University of Siena",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":361,"enrollmentInfo":362,"targetDuration":364,"studyType":75,"phases":4,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":41},"100347685","short-and-long-term-prognosis-of-patients-admitted-to-the-ed-with-acute-heart-failure-100347685","NCT03806972","Short and Long Term Prognosis of Patients Admitted to the ED With Acute Heart Failure","Short and Long Term Prognosis of Patients Admitted to the Emergency Department With Acute Heart Failure","CRF","Inclusion Criteria:\n\n* patients admitted to the ED of Monastir with a principal discharge diagnosis code for HF.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women. Alteration of consciousness GCS \\\u003C 15 Critically ill patients needing immediate mechanical hemodynamic of ventilatory support.\n\nInability to follow instructions or comply with follow-up procedures.","80 Years",{"count":363,"type":22},3000,"12 Months","Heart failure (HF) is the leading cause of hospitalization ,rehospitalization and mortality for adults over 65 years of age.\n\nThis study aimed to assess mortality, and hospitalization rates at 30 days and one year after dicharge of patients with heart failure (HF) with reduced ejection fraction (HFrEF) compared to HF with preserved ejection fraction (HFpEF).",[28],[368],"acute heart failure prognosis","2025-07-17",{"date":371,"type":33},"2025-07-22",{"date":373,"type":33},"2009-06-01",{"date":375,"type":22},"2030-12-01",{"name":377,"class":40},"University of Monastir",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":88},"100593586","phase-3-the-role-of-intraabdominal-pressure-and-point-of-care-ultrasound-to-guide-decongestive-therapy-in-heart-failure-100593586","NCT07008365","The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure","ABDOPOCUS-HF","Inclusion Criteria:\n\n* Men or women over 18 years of age.\n* Diagnosis of heart failure (HF) based on the latest HF guidelines published in 2022.\n* N-terminal pro b-type natriuretic peptide (NT-proBNP) \\> 1000 pg\u002FmL or Brain Natriuretic Peptide (BNP) \\> 250 pg\u002FmL.\n* Placement of a urinary catheter to allow for the measurement of intra-abdominal pressure.\n* Intravascular or mixed congestion pattern, defined as the presence of one or more clinical signs of congestion (edema, ascites, and\u002For pleural effusion).\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient with a stay in the Internal Medicine department \\> 24 hours.\n* Absence of sufficient clinical congestion (ADVOR score = 0 at the time of randomization).\n* Patient\\'s refusal to participate in the clinical trial.\n* Inability or contraindication for urinary catheter placement.\n* Systolic blood pressure at admission \\< 100 mmHg.\n* Heart rate at admission \\> 170 beats per minute (bpm).\n* Cardiogenic shock.\n* Acute myocardial ischemia.\n* Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis).\n* Kidney transplant recipients.\n* Serum hemoglobin \\< 9 g\u002FdL.\n* Pregnancy or breastfeeding.\n* History of hypersensitivity to hydrochlorothiazide or furosemide.\n* Patients admitted from the Intensive Care Unit.\n* Patients with recent cardiac surgery (within the last year) or heart transplant recipients.\n* Need for inotropic support to maintain adequate cardiac and\u002For renal output.","100 Years",{"count":387,"type":22},168,[100],"Systemic venous congestion is the primary therapeutic target of intravenous loop diuretics in patients admitted for acute heart failure (AHF). Despite their utility, a significant proportion of AHF patients are discharged with persistent clinical symptoms of congestion (residual congestion). Therefore, in recent years, there has been a growing focus on the use of tools (biomarkers, clinical ultrasound) that allow us to optimize diuretic treatment and thereby improve the prognosis of AHF patients. The objective is to analyze whether the strategy of guiding intravenous loop diuretic dosing based on intra-abdominal pressure(IAP) measurements and clinical ultrasound is superior to the conventional strategy employed in daily clinical practice. This study is a randomized, multicenter clinical trial involving consecutive patients admitted with a diagnosis of AHF in the Internal Medicine and Cardiology departments. Patients who meet the inclusion criteria, after signing informed consent, will be randomized into two groups: 1) Diuretic treatment guided by usual clinical practice and 2) Treatment guided by intra-abdominal pressure levels and clinical ultrasound (inferior vena cava and portal Doppler). This strategy will be maintained during the first 72 hours of admission, with a thorough analysis of congestion and diuretic response being conducted.",[28,132,391,392],"Intraabdominal Hypertension","Cardio-Renal Syndrome",[394,28,395,396,397],"Point of care Ultrasound (POCUS)","Cardio-renal syndrome","Intraabdominal pressure","Diuretic treatment","2025-06-04",{"date":400,"type":33},"2025-06-06",{"date":402,"type":33},"2025-03-10",{"date":404,"type":22},"2026-12-31",{"name":406,"class":40},"Instituto de Investigación Sanitaria Aragón",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":41},"100561989","cardiac-assessment-and-takotsubo-stunning-among-copd-exacerbations-in-hospital-100561989","NCT06597331","Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital","Prospective Observational Study of Myocardial Stunning in Patients Hospitalized for Exacerbation of Chronic Obstructive Pulmonary Disease","CATCH","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) admitted to hospital ward for AE-COPD\n* Inclusion within 72 hours of admission,\n* Written informed consent\n\nExclusion Criteria:\n\n* Prior acute myocardial infarction or known pre-existing persistent regional wall motion abnormality or left ventricular dysfunction (left ventricular ejection fraction \\[LVEF\\] \\\u003C50%)\n* Expected inability to comply with the protocol (e.g. dementia)",{"count":416,"type":22},200,"The goal of this prospective observational study is to investigate to what extent acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) triggers Takotsubo-stunning, and how this affects the outcome for these patients.\n\nThe main questions it aims to answer are:\n\n1. What is cumulative incidence of Takotsubo-stunning in patients hospitalized for AE-COPD at Sahlgrenska University Hospital\u002FS (Gothenburg, Sweden)?\n2. Among patients hospitalized for AE-COPD at Sahlgrenska University Hospital\u002FS, what is the risk of in-hospital clinical manifestations of acute heart failure in patients with Takotsubo-stunning compared to those without?",[419,420,28],"Chronic Obstructive Pulmonary Disease","Takotsubo Cardiomyopathy",[422,423,424,425,426],"Takotsubo syndrome","COPD","Echocardiography","Screening","Trigger","2025-05-09",{"date":429,"type":33},"2025-05-14",{"date":431,"type":33},"2024-09-23",{"date":433,"type":22},"2027-09-01",{"name":435,"class":40},"Sahlgrenska University Hospital",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":41},"100362504","heart-failure-usb-prediction-and-progression-100362504","NCT04000061","Heart Failure-USB: Prediction and Progression","Inclusion Criteria:\n\n* Patients hospitalized with a primary diagnosis of ACS\n* Patients hospitalized with a primary or secondary diagnosis of AHF\n\nExclusion Criteria:\n\n* Existence of a documented statement of the patient against the scientific use of clinical data",{"count":443,"type":22},6000,"This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and\u002F or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.",[28,446,103],"Acute Coronary Syndrome","2025-04-09",{"date":449,"type":33},"2025-04-10",{"date":451,"type":33},"2019-06-13",{"date":404,"type":22},{"name":454,"class":40},"University Hospital, Basel, Switzerland",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":41},"100528551","naples-federico-ii-intensive-cardiac-care-unit-registry-naples-fed2-iccu-registry-100528551","NCT06162247","Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry)","Inclusion Criteria:\n\n1. Acute cardiovascular disease admitted at our ICCU\n2. Age ≥18 years;\n3. Written informed consent.\n\nExclusion Criteria:\n\n1\\) Patients not providing consent to data collection",{"count":462,"type":22},5000,"This protocol proposes to prospectively evaluate current epidemiology, pharmacologic and invasive management and clinical outcomes of patients with acute cardiovascular diseases admitted at our ICCU.",[465,446,28,159],"Acute Cardiovascular Disease","2025-02-27",{"date":468,"type":33},"2025-03-03",{"date":470,"type":33},"2023-11-20",{"date":472,"type":22},"2033-11-20",{"name":474,"class":40},"Federico II University",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":500},"100528890","phase-4-optimal-diuretic-therapies-for-acute-heart-failure-with-volume-overload-100528890","NCT06166654","Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload","Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload - A Randomized Clinical Trial","DRAIN-AHF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload.\n3. Display risk of diuretic resistance, characterized by:\n\n   1. Daily loop-diuretics administration for a minimum of 7 days before admission, or\n   2. Insufficient decongestion observed in the preceding 24 hours (weight reduction \\\u003C500g or negative fluid balance \\\u003C1L) despite being treated with high-dose IV loop diuretic (equivalent to ≥120 mg IV furosemide within 24 hours).\n4. Clinical signs of congestion, indicated by one or more of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiological\u002Fultrasonic evidence of pulmonary congestion.\n\nExclusion Criteria:\n\n1. Acute coronary syndrome\n2. Systolic blood pressure \\\u003C85 mmHg\n3. Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion\n4. Treatment with acetazolamide or metolazone during the index hospitalization prior to randomization\n5. Known allergy to any of the used drugs\n6. Severe hypokalemia (\\\u003C2.5 mmol\u002Fl) or severe hyponatremia (\\\u003C125 mmol\u002Fl)\n7. Severe hepatic impairment or liver cirrhosis\n8. Known pregnancy",{"count":484,"type":22},939,[53],"Aim to identify the best strategy for treating acute heart failure (AHF) with volume overload, particularly focusing on patients resistant to standard loop-diuretics. The trial is a double-blinded, randomized, controlled, multicenter study. Its primary objective is to compare the efficacy of loop-diuretics combined with either Metolazone or Acetazolamide, against loop-diuretics alone. The trial will also determine the optimal type of loop-diuretic to use.\n\nEligible participants include adults over 18 years hospitalized with AHF and volume overload, showing signs of congestion and at risk of diuretic resistance. Exclusions apply to those with acute coronary syndrome, low systolic blood pressure, prior renal therapy, or previous treatment with Acetazolamide or Metolazone.\n\nThe primary outcome is the number of days alive and out-of-hospital by day 30. Secondary outcomes include a composite clinical benefit at 30 days, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and successful decongestion 72 hours post-inclusion.\n\nThe trial aims to enroll about 1,041,939 patients across three treatment arms over three years. The minimal important difference is set as a reduction in out-of-hospital days by at least two days, with an anticipated low dropout rate. The study's power is calculated to be 80% with an adjusted alpha level for comparing the three diuretic groups.",[28],[134,489,490],"decongestion","diuretic","2025-02-19",{"date":493,"type":33},"2025-02-20",{"date":495,"type":33},"2024-09-05",{"date":497,"type":22},"2027-09-30",{"name":499,"class":40},"Johannes Grand",3,{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":41},"100576274","phase-2-assessing-the-clinical-outcomes-of-dapagliflozin-versus-acetazolamide-in-patients-with-acute-heart-failure-100576274","NCT06783166","Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure","Inclusion Criteria:\n\n1. Adults aged 18 years or older who are hospitalized for hypervolemic AHF, with evidence of congestion defined as either:\n\n   * 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \\> 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound. OR\n   * If pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmHg plus a systemic physical exam finding of hypervolemia from the list above.\n2. Randomized within 24 hours of hospitalization for AHF.\n3. Planned use of IV loop diuretic therapy during current hospitalization\n4. Estimated glomerular filtration rate (eGFR) of at least 30 ml\u002Fmin\u002F1.73m2 by the MDRD equation.\n\nExclusion Criteria:\n\n1. Unable to follow instructions.\n2. Treated with any proximal tubular diuretics.\n3. Systolic blood pressure of less than 90 mm Hg.\n4. An estimated glomerular filtration rate (GFR) of less than 20 ml per 1.73 m2 of body-surface area.\n5. Type 1 diabetes mellitus.\n6. Dyspnea is primarily due to non-cardiac causes.\n7. Cardiogenic shock.\n8. Acute coronary syndrome within 30 days prior to randomization.\n9. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization.\n10. Signs of ketoacidosis and\u002For hyperosmolar hyperglycemic syndrome (pH\\>7.30 and glucose \\>15 mmol\u002FL and HCO3\\>18 mmol\u002FL).\n11. Pregnant or nursing (lactating) women.",{"count":508,"type":22},100,[510,100],"PHASE2","This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.",[28],"2025-01-14",{"date":515,"type":33},"2025-01-20",{"date":517,"type":33},"2024-08-15",{"date":519,"type":22},"2025-08-01",{"name":521,"class":40},"Mansoura University",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":18,"minAge":271,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":41},"100516615","prognostic-markers-of-acute-heart-failure-with-chronic-kidney-disease-100516615","NCT06006819","Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease","Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease","Inclusion Criteria:\n\n* hospitalized for acute heart failure\n\nExclusion Criteria:\n\n* initial serum NT-proBNP level \\\u003C300ng\u002Fml, pregnancy, amputated, and end-stage renal disease under regular dialysis","90 Years",{"count":531,"type":22},155,"Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.",[534,28,535],"Chronic Kidney Diseases","Biomarker","2024-08-21",{"date":538,"type":33},"2024-08-23",{"date":540,"type":33},"2023-01-01",{"date":542,"type":22},"2025-12-23",{"name":544,"class":40},"Cheng-Hsin General Hospital",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":529,"enrollmentInfo":552,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":553,"conditions":554,"keywords":555,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":41},"100553864","liver-function-abnormalities-in-patients-with-acute-heart-failure-100553864","NCT06491628","Liver Function Abnormalities in Patients With Acute Heart Failure","Liver Function Abnormalities in Patients With Acute Heart Failure in Sohag University Hospitals","Inclusion Criteria:\n\n* patients aged 18 yrs or older presenting with AHF\n\nExclusion Criteria:\n\n* Congenital heart disease\n* acute and chronic liver diseases",{"count":508,"type":22},"The aim of this study is to evaluate liver function test abnormalities and to identify associated cardiac and non cardiac factors mediating hepatic impairment in acute heart failure patients",[28],[556],"LFTs, AHF","2024-07-08",{"date":559,"type":33},"2024-07-10",{"date":561,"type":22},"2024-07-01",{"date":563,"type":22},"2025-08",{"name":565,"class":40},"Sohag University",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":572,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":41},"100550468","short-term-outcome-of-acute-heart-failure-in-diabetic-and-non-diabetic-patients-100550468","NCT06447467","Short Term Outcome of Acute Heart Failure in Diabetic and Non Diabetic Patients","Inclusion Criteria:\n\n* Aged 18 years old or older .\n* Admitted to the Coronary Care Unit with acute HF.\n* Patients with new onset heart failure.\n* Decompensated chronic HF.\n\nExclusion Criteria:\n\n* Aged under 18 years old.\n* Patients with chronic HF",true,{"count":508,"type":22},"Around 26 million people suffer from heart failure (HF) globally, and the prevalence is increasing with an increasing longevity, prevalence of risk factors, and improved survival in patients with cardiovascular diseases In Egypt, HF is the primary cause of hospitalization among patients aged \\> 65 years . Hospitalization for HF is associated with a high mortality and rate of re-hospitalization . Around 75% patients with HF have ≥ 1 comorbidity, and these comorbidities make overall clinical outcomes worse . In a recent meta-analysis, patients with diabetes mellitus (DM) were suggested to have a two-fold increase in the risk of HF . DM is present in \\~ 35% patients hospitalized with acute HF . Multiple factors such as ischemia, hypertension, and extracellular fluid volume expansion are involved in the pathogenesis of HF in DM.",[28,576],"Diabetes Mellitus","2024-06-17",{"date":579,"type":33},"2024-06-20",{"date":581,"type":33},"2024-06-01",{"date":583,"type":22},"2024-12-01",{"name":565,"class":40},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":592,"targetDuration":364,"studyType":75,"phases":4,"briefSummary":593,"conditions":594,"keywords":598,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":611},"100346632","the-excel-registry-of-patients-requiring-ecmo-100346632","NCT03793257","The EXCEL Registry of Patients Requiring ECMO","The EXCEL Registry: A Comprehensive Binational Registry on the Treatment and Outcomes of Patients Requiring ECMO","Inclusion Criteria:\n\n* Patients admitted to adult hospitals and receive ECMO in Australia and New Zealand\n\nNil Exclusion Criteria",{"count":363,"type":22},"ECMO is associated with significant costs, risks and requires specialist training and expertise. EXCEL is a novel, high-quality, detailed prospective registry of patients requiring ECMO in Australia and New Zealand. The registry provides information on patient selection, complications, costs and patient reported outcome measures. EXCEL uses the Theoretical Domains Framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence",[595,596,28,597],"Critically Ill","Acute Respiratory Failure","Cardiac Arrest",[599,600,601,602],"Intensive Care","Critical Care","Extracorporeal Membrane Oxygenation","Extracorporeal Life Support","2023-09-13",{"date":605,"type":33},"2023-09-15",{"date":607,"type":33},"2019-02-01",{"date":86,"type":22},{"name":610,"class":40},"Australian and New Zealand Intensive Care Research Centre",29,{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":41},"100388867","acute-heart-failure-with-preserved-ejection-fraction---congestion-discharge-evaluation-100388867","NCT04343430","Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation","Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation: Evaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë à Fraction d'éjection préservée","AHF-CODE-P","Inclusion Criteria:\n\n* Patients hospitalised for acute heart failure.\n* Patient with preserved ejection fraction (FE ≥ 50%).\n* Patients considered clinically discharging from hospitalisation for acute heart failure.\n* Age ≥18 years\n* Patients having received complete information regarding the study design and having signed their informed consent form.\n* Patient affiliated to or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* Comorbidity for which the life expectancy is ≤ 3 months\n* Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \\\u003C15 ml\u002Fmin\u002Fm² at inclusion.\n* History of lobectomy or pneumonectomy lung surgery\n* Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.\n* Pregnant woman, parturient or nursing mother\n* Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n* Adult person who is unable to give consent\n* Person deprived of liberty by a judicial or administrative decision,\n* Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.",{"count":621,"type":22},170,[25],"The AHF-CODE preserved study is a prospective, non-randomized, monocenter study performed in patients with heart failure with preserved ejection fraction admitted for worsening heart failure.\n\nThe main objective of the AHF-CODE preserved study is to identify congestion markers (clinical, biological and ultrasound) at the end of hospitalization for acute heart failure that are associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge.",[28],"2023-06-02",{"date":627,"type":33},"2023-06-05",{"date":629,"type":33},"2020-08-29",{"date":631,"type":22},"2028-08-29",{"name":633,"class":40},"Central Hospital, Nancy, France"]